Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Castration-Sensitive Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Post-approval studies (Phase 4)UnknownNCT04601441
What this trial is testing

Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan

Who this might be right for
Metastatic Castration-sensitive Prostate Cancer
Kindai University 100
Not applicableNot Yet RecruitingNCT07804030
What this trial is testing

AI-Assisted Patient Support in mHSPC

Who this might be right for
Metastatic Prostate Cancer
Fudan University 160
Not applicableLooking for participantsNCT06334120
What this trial is testing

An Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea

Who this might be right for
Non-metastatic Castration-resistant Prostate CancerMetastatic Hormone-sensitive Prostate Cancer
Bayer 600
Large-scale testing (Phase 3)Active Not RecruitingNCT04076059
What this trial is testing

An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone Sensitive Prostate Cancer
Astellas (Beijing) Pharmaceutical R&D Co., Ltd. 180
Testing effectiveness (Phase 2)Study completedNCT01875250
What this trial is testing

Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Prostate Cancer
National Cancer Institute (NCI) 38
Not applicableLooking for participantsNCT06306612
What this trial is testing

CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer

Who this might be right for
Prostate Cancer
RenJi Hospital 192
Testing effectiveness (Phase 2)Looking for participantsNCT07190300
What this trial is testing

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Novartis Pharmaceuticals 181
Not applicableNot Yet RecruitingNCT07806591
What this trial is testing

Darolutamide Plus Androgen Deprivation Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer in India

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Bayer 50
Early research (Phase 1)Ended earlyNCT05733351
What this trial is testing

Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Emory University 4
Testing effectiveness (Phase 2)Active Not RecruitingNCT04267887
What this trial is testing

Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8
OHSU Knight Cancer Institute 7
Testing effectiveness (Phase 2)Looking for participantsNCT05914116
What this trial is testing

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Who this might be right for
Advanced Solid Tumors
DualityBio Inc. 862
Not applicableActive Not RecruitingNCT07344779
What this trial is testing

Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice

Who this might be right for
Metastatic Hormone-Sensitive Prostate Cancer
Bayer 1,600
Testing effectiveness (Phase 2)Study completedNCT03899467
What this trial is testing

The Safety and Tolerability of GT0918 in Subjects With mHSPC and mCRPC

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Suzhou Kintor Pharmaceutical Inc, 61
Testing effectiveness (Phase 2)Active Not RecruitingNCT04126070
What this trial is testing

Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

Who this might be right for
Hormone Sensitive Prostate CancerProstate AdenocarcinomaMetastasis Prostate Adenocarcinoma
Xiao X. Wei, MD 47
Testing effectiveness (Phase 2)Study completedNCT02059213
What this trial is testing

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Who this might be right for
Prostate Cancer
University of Michigan Rogel Cancer Center 72
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07268794
What this trial is testing

CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Prostate CancerProstate Cancer (Adenocarcinoma)Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Fudan University 112
Testing effectiveness (Phase 2)Looking for participantsNCT05720130
What this trial is testing

Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Hormone Sensitive Prostate Cancer
AdvanCell Pty Limited 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT05241860
What this trial is testing

Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)

Who this might be right for
Castration-Sensitive Prostate CarcinomaMetastatic Prostate CarcinomaStage IV Prostate Cancer AJCC v8+2 more
Alliance for Clinical Trials in Oncology 79
Not applicableNot Yet RecruitingNCT07031258
What this trial is testing

Evaluation of the Efficacy of Darolutamide Triplet Therapy in Patients With Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Metastatic Hormone-sensitive Prostate CancerDarolutamide (DARO) in Combination With Androgen-deprivation Therapy (ADT) and Docetaxel (DOC)
Nanfang Hospital, Southern Medical University 50
Large-scale testing (Phase 3)Study completedNCT04736199
What this trial is testing

Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate Cancer

Who this might be right for
Prostatic Neoplasms
Bayer 669
Next Page